Zhaoke Ophthalmology partners with TSH Biopharm for BRIMOCHOL™ PF in Taiwan

Zhaoke Ophthalmology Limited has announced a strategic partnership with Taiwan-based TSH Biopharm Corporation Limited to commercialize BRIMOCHOL™ PF in Taiwan. This collaboration grants TSH Biopharm exclusive distribution rights, covering the registration, import, promotion, distribution, marketing, and sale of the investigational, preservative-free, once-daily eyedrop designed to correct near vision loss associated with aging.

The partnership leverages TSH Biopharm's expertise in chronic diseases and precision medicine. BRIMOCHOL™ PF, developed by Tenpoint Therapeutics, Ltd., recently had its New Drug Application (NDA) accepted by the U.S. FDA, with a Prescription Drug User Fee Act (PDUFA) date set for January 28, 2026. The product aims to address presbyopia, a condition affecting billions globally, including approximately 600m adults in China, South Korea, and Southeast Asia.

BRIMOCHOL™ PF is the subject of the BRIO-II Phase 3 study, a multicenter, randomized, double-masked trial that enrolled 629 subjects across forty-seven sites in the United States. This study evaluates the carbachol/brimonidine tartrate fixed-dose combination against carbachol monotherapy and vehicle topical ophthalmic solutions in individuals with emmetropic phakic or pseudophakic presbyopia.